Wyeth and Progenics Pharmaceuticals initiated three new clinical studies for their investigational drug, methylnaltrexone, a peripherally acting mu-opioid receptor antagonist. Two of these trials will study the use of subcutaneous methylnaltrexone for treating opioid-induced constipation (OIC) in patients outside of the palliative care population included in the first NDA submission. The third trial will investigate methylnaltrexone for managing post-operative ileus (POI). The companies are curr...